_(3).png)
_(4).png){kind=logo}
Loading Shopping Cart Items...
FREE FOR MEMBERS!
Description: Introduction of next-generation sequencing (NGS)-based mutation profiling has improved prognostic risk stratification of patients with acute myeloid leukemia (AML), thus helping the selection of consolidation treatment option between allogeneic hematopoietic stem cell transplantation (HCT) and chemotherapy. While gene mutation-targeted therapeutic agents are being developed, thus providing a novel treatment option in the patients having mutations which are detected by NGS. Consequently NGS-based mutation profiling has been implemented in the clinical practice of AML therapy. An overview of currently available technology for MRD monitoring, including multiple color flow cytometry, PCR and NGS will be provided.
Start Date: Upon registration
Completion: Up to 52 weeks
At the end of this webinar you will learn:
Speaker: Dr. Dennis Kim, Princess Margaret Hospital
Dr. Dennis Kim is the Associate Professor, Department of Medical Oncology & Hematology at the Princess Margaret Cancer Centre. He graduated from Kyungpook National University, School of Medicine in Korea in 1995 and did his residency in Internal Medicine.
After working as the Assistant Professor, Division of Hematology/Oncology, Department of Medicine at the Sungkyunkwan University School of Medicine in Seoul, Korea until 2011, he came to Canada to work at the Princess Margaret Cancer Centre and has been there since. He has published over 200 peer-reviewed papers as of June 2020 and has been the Principal Investigator in multiple clinical trials.
Recorded: February 4, 2021
PEP hours: 1.0
CPS credits: 0
*Note: PEP hours and/or CPS credits will only be awarded upon successful completion of the quiz.
Loading Shopping Cart Items...